Search results
Results from the WOW.Com Content Network
Autologous chondrocyte implantation (ACI, ATC code M09AX02 ()) is a biomedical treatment that repairs damages in articular cartilage.ACI provides pain relief while at the same time slowing down the progression or considerably delaying partial or total joint replacement (knee replacement) surgery.
There are several different repair options available for cartilage damage or failure. "Maci" or autologous cultured chondrocytes on porcine collagen membrane, is a treatment to correct cartilage defects in the knee. This treatment has been approved by the Food and Drug Administration in 2016 for adult treatment only. [1]
This short-term solution is not considered as an articular cartilage repair procedure but rather a palliative treatment to reduce pain, mechanical restriction and inflammation. Lavage focuses on removing degenerative articular cartilage flaps and fibrous tissue. The main target groups are patients with very small defects of the articular cartilage.
Articular cartilage stem cell paste grafting was initially described by Kevin R. Stone M.D., a San Francisco-based orthopedic surgeon, in 1997 . The technique was devised in response to reports that many of the contemporary cartilage restoration procedures lead to the development of fibrocartilage, not true hyaline articular cartilage. Knowing ...
An articular cartilage defect that initially may be small still has the potential to have a physical and chemical "domino effect" on the surrounding "normal" articular cartilage. [2] Pitkin et al. (2014) discovered a potential etiology for articular cartilage damage. When the interarticular transmission of pressures is interrupted so that ...
They reported a case study in which a full-thickness defect in the articular cartilage of a human knee was successfully repaired. [23] While the use of cultured mesenchymal stem cells has shown promising results, a more recent study using uncultured MSC's has resulted in full-thickness, histologically confirmed hyaline cartilage regrowth.
Phase 2 study completed in 2017 and 5 year follow-up published in 2021, [30] demonstrated clear dose- and frequency-dependent improvements in cartilage thickness (primary endpoint), complete arrest in progression to joint replacement (in the high dose treatment groups), and improvements in the WOMAC pain survey for high-risk patients (secondary ...
The procedure is less effective in treating older patients, overweight patients, or a cartilage lesion larger than 2.5 cm. [11] Further on, chances are high that after only 1 or 2 years of the surgery symptoms start to return as the fibrocartilage wears away, forcing the patient to reengage in articular cartilage repair.